207 related articles for article (PubMed ID: 26646272)
21. Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.
Tveteraas IH; Aasrum M; Brusevold IJ; Ødegård J; Christoffersen T; Sandnes D
Tumour Biol; 2016 Feb; 37(2):2519-26. PubMed ID: 26386720
[TBL] [Abstract][Full Text] [Related]
22. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
25. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer.
Seshacharyulu P; Ponnusamy MP; Rachagani S; Lakshmanan I; Haridas D; Yan Y; Ganti AK; Batra SK
Oncotarget; 2015 Mar; 6(7):5164-81. PubMed ID: 25686822
[TBL] [Abstract][Full Text] [Related]
26. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
27. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.
Servidei T; Meco D; Trivieri N; Patriarca V; Vellone VG; Zannoni GF; Lamorte G; Pallini R; Riccardi R
Int J Cancer; 2012 Sep; 131(5):E791-803. PubMed ID: 22120695
[TBL] [Abstract][Full Text] [Related]
28. Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer.
Xin B; He X; Wang J; Cai J; Wei W; Zhang T; Shen X
Pancreatology; 2016; 16(6):1005-1014. PubMed ID: 27654574
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Kim YM; Park SY; Pyo H
Mol Cancer Res; 2009 Aug; 7(8):1367-77. PubMed ID: 19671676
[TBL] [Abstract][Full Text] [Related]
30. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
[TBL] [Abstract][Full Text] [Related]
33. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
34. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
Zhang B; Huang H; Xie J; Xu C; Chen M; Wang C; Yang A; Yin Q
Oncol Rep; 2012 Mar; 27(3):891-7. PubMed ID: 22139427
[TBL] [Abstract][Full Text] [Related]
35. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.
Li J; Li Y; Feng ZQ; Chen XG
Cancer Lett; 2009 Jul; 279(2):213-20. PubMed ID: 19299077
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
38. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.
Moon DO; Kim MO; Heo MS; Lee JD; Choi YH; Kim GY
Arch Pharm Res; 2009 Oct; 32(10):1351-60. PubMed ID: 19898796
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
